American Heart Journal
Volume 154, Issue 4 , Pages 624-631 , October 2007

Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

  • Ronald V. Lacro, MD

      Affiliations

    • Children's Hospital Boston and Harvard Medical School, Boston, MA
    • Corresponding Author InformationReprint requests: Ronald V. Lacro, MD, Department of Cardiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115.
    • ,
  • Harry C. Dietz, MD

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Lisa M. Wruck, PhD

      Affiliations

    • New England Research Institutes, Watertown, MA
    • ,
  • Timothy J. Bradley, MD

      Affiliations

    • The Hospital for Sick Children, Toronto, Ontario, Canada
    • ,
  • Steven D. Colan, MD

      Affiliations

    • Children's Hospital Boston and Harvard Medical School, Boston, MA
    • New England Research Institutes, Watertown, MA
    • ,
  • Richard B. Devereux, MD

      Affiliations

    • Weill Medical College of Cornell University, New York, NY
    • ,
  • Gloria L. Klein, MS

      Affiliations

    • New England Research Institutes, Watertown, MA
    • ,
  • Jennifer S. Li, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • L. LuAnn Minich, MD

      Affiliations

    • Primary Children's Medical Center, Salt Lake City, UT
    • ,
  • Stephen M. Paridon, MD

      Affiliations

    • The Children's Hospital of Philadelphia, Philadelphia, PA
    • ,
  • Gail D. Pearson, MD, ScD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, MD
    • ,
  • Beth F. Printz, MD

      Affiliations

    • Columbia University Medical Center, New York, NY
    • ,
  • Reed E. Pyeritz, MD, PhD

      Affiliations

    • University of Pennsylvania, Philadelphia, PA
    • ,
  • Elizabeth Radojewski, RN

      Affiliations

    • The Hospital for Sick Children, Toronto, Ontario, Canada
    • ,
  • Mary J. Roman, MD

      Affiliations

    • Weill Medical College of Cornell University, New York, NY
    • ,
  • J. Philip Saul, MD

      Affiliations

    • Medical University of South Carolina, Charleston, SC
    • ,
  • Mario P. Stylianou, PhD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, MD
    • ,
  • Lynn Mahony, MD,

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, TX
    • ,
  • for the Pediatric Heart Network Investigators

Received 5 February 2007 ,Accepted 20 June 2007.

References 

  1. Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366:1965–1976
  2. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157–160
  3. Pyeritz RE. Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. Semin Thorac Cardiovasc Surg. 1993;5:11–16
  4. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med. 1999;340:1307–1313
  5. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–339
  6. Collod-Beroud G, Beroud C, Ades L, et al. Marfan database (third edition): new mutations and new routines for the software. Nucleic Acids Res. 1998;26:229–233
  7. Visconti RP, Barth JL, Keeley FW, et al. Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development. Matrix Biol. 2003;22:109–121
  8. Sakai LY, Keene DR, Glanville RW, et al. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem. 1991;266:14763–14770
  9. Munger JS, Harpel JG, Gleizes PE, et al. Latent transforming growth factor–beta: structural features and mechanisms of activation. Kidney Int. 1997;51:1376–1382
  10. Bonewald LF. Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr. 1999;9:33–44
  11. Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta–binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem. 2003;278:2750–2757
  12. Dallas SL, Keene DR, Bruder SP, et al. Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res. 2000;15:68–81
  13. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407–411
  14. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275–281
  15. Ng CM, Cheng A, Myers LA, et al. TGF-beta–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114:1586–1592
  16. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–121
  17. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330:1335–1341
  18. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol. 1999;83:1364–1368
  19. Salim MA, Alpert BS, Ward JC, et al. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol. 1994;74:629–633
  20. Selamet Tierney ES, Feingold B, Printz BF, et al. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr. 2007;150:77–82
  21. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol. 2005;95:1125–1127
  22. Dean JC. Management of Marfan syndrome. Heart. 2002;88:97–103
  23. Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation. 2001;104:I282–I287
  24. Mahony L, Sleeper LA, Anderson PA, et al. The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol. 2006;27:191–198
  25. de Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62:417–426
  26. Greally, MT. Shprintzen-Goldberg syndrome. GeneReviews at GeneTests: Medical Genetics Information Resource (database online). 1-13-2006. University of Washington, Seattle. 1997-2006. 3-29-2006.
  27. Erkula G, Jones KB, Sponseller PD, et al. Growth and maturation in Marfan syndrome. Am J Med Genet. 2002;109:100–115
  28. Amery A, De Plaen JF, Lijnen P, et al. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther. 1977;21:691–699
  29. Tuininga YS, Crijns HJ, Brouwer J, et al. Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation. 1995;92:3415–3423
  30. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73:17–27
  31. Nollen GJ, Groenink M, Tijssen JG, et al. Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J. 2004;25:1146–1152
  32. Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg. 2006;81:169–177
  33. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken (NJ): John Wiley & Sons, Inc; 2004;
  34. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556.
  35. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–663

 This work was supported by U01 HL068285 (Lacro); U01 HL068270 (Wruck, Mahony, Colan, Klein), U01 HL068269 (Li), U01 HL068292 (Minich), U01 HL068290 (Printz, Devereux, Roman), U01 HL068288 (Bradley), U01 HL068281 (Saul), and U01 HL068279 (Paridon, Pyeritz) from the National Heart, Lung, and Blood Institute (Bethesda, MD), the Howard Hughes Medical Institute (Baltimore, MD) (Dietz); the National Marfan Foundation (Port Washington, NY) (Dietz); and the Smilow Center for Marfan Syndrome Research (Baltimore, MD) (Dietz).

PII: S0002-8703(07)00528-5

doi: 10.1016/j.ahj.2007.06.024

American Heart Journal
Volume 154, Issue 4 , Pages 624-631 , October 2007

Article Tools

* Image Usage & Resolution